Rory M. Shallis

Jan 8, 2025 | onclive.com | Rory M. Shallis

CommentaryVideoJanuary 8, 2025Author(s):Rory Shallis, MD, discusses the addition of pembrolizumab to azacitidine citidine and venetoclax in patients with acute myeloid leukemia. “[This was] a negative trial, which is a disappointment, but we learn a lot from these trials. This is a trial that is enriched for a number of correlative analyses being done through the CIMAC collaboration with a number of outstanding laboratory and translational colleagues.

Aug 8, 2024 | onclive.com | Rory M. Shallis

Rory Shallis, MD, assistant professor, medicine (hematology), Yale School of Medicine, Yale New Haven Health, discusses the utility of luspatercept-aamt (Reblozyl) as evaluated in the phase 3 ELEMENT-MDS trial (NCT05949684) for patients with myelodysplastic syndrome (MDS).

May 16, 2024 | onlinelibrary.wiley.com | Rebecca Bystrom |Jan Philipp Bewersdorf |Shai Shimony |Rory M. Shallis |Yiwen Liu |guillaume BERTON | +9 more

To the Editor: Intensive induction chemotherapy followed by consolidation therapy with additional chemotherapy and/or an allogeneic hematopoietic stem cell transplant (allo-SCT) is the standard of care for younger and fit patients with acute myeloid leukemia (AML).1 For older AML patients or those deemed unfit for intensive chemotherapy, the addition of the BCL2 inhibitor venetoclax to hypomethylating agents (HMA + VEN) has been shown to improve overall survival (OS) compared with HMA...

Feb 20, 2024 | nature.com | Shai Shimony |Jan Philipp Bewersdorf |Rory M. Shallis |Guido Marcucci |Daniel DeAngelo |Donna S. Neuberg | +1 more

AbstractMolecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395) treated with daunorubicin and cytarabine (7 + 3, n = 167), liposomal daunorubicin and cytarabine (CPX-351, n = 66) or hypomethylating agents (HMA) + venetoclax (VEN) (n = 162). Median overall survival (OS) was comparable between treatment groups among patients aged >60 years.

Feb 12, 2024 | onlinelibrary.wiley.com | Yasmin Abaza |Eric S. Winer |Rory M. Shallis |Andrew Matthews |Talha Badar |Emily M. Geramita | +6 more

1 INTRODUCTION Acute myeloid leukemia (AML) is primarily a disease of the elderly with a median age at diagnosis of 69 years.1 Treatment of patients with AML ≥75 years of age, who are truly unfit for intensive chemotherapy, is challenging given the higher incidence of adverse risk disease, comorbidities, poor performance status, and compromised organ function.2-4 Although the outcomes of AML have significantly improved over the past 5 decades, the long-term survival remains poor with the...